Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Dose-escalation Phase I/II Clinical Study to Evaluate the Safety, Preliminary Efficacy and Immunogenicity of SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I

NCT07554924 is registered in ClinicalTrials.gov with Lanyue Biotech (Hangzhou) Co., Ltd. as lead sponsor.

NCT NCT07554924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07554924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Dose-escalation Phase I/II Clinical Study to Evaluate the Safety, Preliminary Efficacy and Immunogenicity of SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
Lead sponsor
Lanyue Biotech (Hangzhou) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 15, 2026
Completion date
May 25, 2029
Enrollment
11 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy 1